12/4/2019 7:45:59 AM
Revance Therapeutics Prices Public Offering Of 6.5 Mln Shares At $17/Shr
12/3/2019 4:08:08 PM
Revance Announces Proposed Public Offering Of Common Stock
12/2/2019 8:14:30 AM
Revance Therapeutics Promotes Dustin Sjuts To Role Of Chief Commercial Officer, Aesthetics & Therapeutics
11/25/2019 8:04:59 AM
Revance Submits BLA To The FDA For DAXI To Treat Glabellar (Frown) Lines
11/4/2019 8:06:21 AM
Revance Announces Publication Of SAKURA 1 And SAKURA 2 Results In Plastic And Reconstructive Surgery
10/14/2019 8:12:21 AM
Revance Appoints Mark Foley As President And CEO, Replacing Dan Browne
1/22/2019 4:10:02 PM
Revance Announces Closing Of Public Offering Of Common Stock
1/17/2019 6:53:06 AM
Revance Therapeutics Prices Public Offering Of 5.88 Mln Shares At $17.00 Per Share
12/4/2018 8:09:25 AM
Revance Therapeutics Enters License Agreement With Fosun Pharma Industrial
10/11/2018 8:33:24 AM
Revance Therapeutics Appoints Tobin Schilke As CFO
5/29/2018 7:02:27 AM
Revance Therapeutics CFO Lauren Silvernail Resigns
3/1/2018 9:04:13 AM
William Blair Reiterates Revance Therapeutics, Inc. (RVNC) At Outperform
2/28/2018 4:07:06 PM
Mylan To Develop Biosimilar Of BOTOX Through Collaboration And License Agreement With Revance Therapeutics
1/9/2018 6:06:39 AM
Hercules Capital Achieves More Than $880 Mln In New Commitments In 2017
1/8/2018 8:37:08 AM
Revance Announces Interim Phase 2a Results For RT002 In Treating Plantar Fasciitis